Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial

已完结 10 由 Holly 发布于 2025/1/13 10:47:58

DOI:10.1016/s2213-2600(24)00324-2
作者：Dave Singh, Christopher E Brightling, Klaus F Rabe, MeiLan K Han, Stephanie A Christenson, M Bradley Drummond, Alberto Papi, Ian D Pavord, Nestor A Molfino, Gun Almqvist, Ales Kotalik, ?sa Hellqvist,
文献类型：期刊论文
补充材料：只需要正文

Elsevier

Abstract：BackgroundTezepelumab is a human monoclonal antibody that blocks thymic stromal lymphopoietin, which has shown increased expression in patients with chronic obstructive pulmonary disease (CO

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:知网刺槐人工林根际细菌及生态功能特征研究